Cost-Effectiveness and Budget Impact Analysis of the Trivalent Adjuvanted Influenza Vaccine in People over 50 Years of Age for Argentina

This peer-reviewed article assesses the cost-effectiveness and budget impact of introducing the adjuvanted trivalent influenza vaccine (aTIV) for adults aged 50–64 with risk factors in Argentina, alongside its use in adults aged 65 years and older. Using a decision-analytic static model from the Argentine healthcare system perspective, the authors compared the health and economic outcomes of aTIV with the standard-dose trivalent influenza vaccine (SD-TIV) over one influenza season and conducted a five-year budget impact analysis under different vaccine uptake scenarios.

Key findings

• Introducing aTIV for adults aged ≥50 with risk factors would generate a lifetime gain of 1489 quality-adjusted life years (QALYs) compared with SD-TIV.
• The strategy would result in an incremental cost-effectiveness ratio (ICER) of USD 5599 per QALY gained, which is below Argentina’s cost-effectiveness threshold.
• Higher vaccine acquisition costs are largely offset by reductions in outpatient visits and hospitalizations related to influenza complications.
• The five-year budget impact analysis indicates only a modest increase in healthcare spending, with an average annual per-member-per-month cost of approximately USD 0.0025.
• Overall results suggest that adopting aTIV for high-risk adults aged 50–64 would be both cost-effective and financially manageable within Argentina’s healthcare system.

Thumbnail image credit: Shutterstock / BlurryMe